anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Overactive bladder syndrome is a common chronic condition with a significant impact on quality of life and economic burden. Persistence with pharmacologic therapy has been limited by efficacy and side effects. A greater understanding of the pathophysiology of overactive bladder has led to the initial evaluation of several drugs affecting ion channels, the autonomic nervous system, and enzymes which may provide useful alternatives for the management of overactive bladder.
AREAS COVERED: A comprehensive review was performed using PubMed and Cochrane databases as well as reviewing clinical trials in the United States. The current standard of care for overactive bladder will be discussed, but this paper focuses on investigational drugs currently in preclinical studies and phase I and II clinical trials.
EXPERT OPINION: Current therapies for overactive bladder have limitations in efficacy and side effects. A greater understanding of the pathophysiology of overactive bladder has identified the role(s) of other pathways in the overactive bladder syndrome. Targeting alternative pathways including ion channels and enzymes may provide alternative therapies of overactive bladder and a more tailored approach to the management of overactive bladder.
The invention belongs to the technical field of health foods and in particular relates to compound brain-strengthening hair-blacking prepared radix polygoni multiflori granules and a preparation method thereof. The compound brain-strengthening hair-blacking prepared radix polygoni multiflori granules are mainly prepared from prepared extracts of radix polygoni multiflori, black sesame, radix astragali and salviae miltiorrhizae, and proper assistants such as xylitol. The compound brain-strengthening hair-blacking prepared radix polygoni multiflori granules are prepared according to the theory of traditional Chinese medicine (namely the monarch, minister, assistant and guide compatibility principle), and has the health-care efficacies of strengthening brain, blacking hair, and preventing lapse of memory and early hair whitening. The invention also provides the preparation method of the compound brain-strengthening hair-blacking prepared radix polygoni multiflori granules. The preparation method comprises the steps of well choosing prepared radix polygoni multiflori, black sesame, radix astragali and salviae miltiorrhizae, drying, mixing in a weight ratio and crushing; extracting by a high-pressure extraction milling; adding the assistants in a weight ratio; and uniformly mixing the assistants with the crushed extracts of prepared radix polygoni multiflori, black sesame, radix astragali and salviae miltiorrhizae, adding medicinal ethyl alcohol to prepare a soft material, and finally, preparing the soft material into the granules. The preparation method is simple and the production efficiency is high.
The present invention relates to an adenosine cyclophosphate injection and a preparing process thereof. According to the invention, acidum citricum is added into a magnetic stirring pot. Injection water with confect amount of 50% is added and dissolved. The adenosine cyclophosphate and meglumine are added into the solution. The obtained solution is mixed to be dissolved. The 0.02% of activated carbon with needle use in volume is added. The mixture is mixed for 30 minutes. The mixture is preliminarily filtered fro removing carbon. The adenosine cyclophosphate injection is prepared for standby. The injection water is added to the total amount. The pH value is adjusted to 6.0-6.5 by sodium hydroxide solution with concentration of 10%. The colorless transparent injection is prepared. The adenosine cyclophosphate injection of the invention not only has the advantages of straight function, high speed, etc., but also has the advantages of little adverse effect, normal temperature transportation and normal preserving, thereby increasing the stability and safety of the product.
BACKGROUND: Obesity is a global epidemic, leading to an increasing focus on interventions like bariatric surgeries. Despite this, there's a noticeable gap in understanding the demographic distribution of patients in clinical trials for bariatric surgery.
METHODS: We conducted a comprehensive analysis of 117 registered randomized clinical trials related to bariatric surgery on ClinicalTrials.gov. We extracted demographic information, including age, sex, race, and ethnicity, and performed descriptive statistical analyses.
RESULTS: The analysis covered 8,418 participants. The mean age was 43.8 years, with a substantial majority (93.8 ​%) falling within the 18-65 age group. Females comprised 74.9 ​% of participants, surpassing real-world estimates. Racially, 65.3 ​% of participants were White, while African Americans represented 18.5 ​%, Asians 1.2 ​%, Native Hawaiians 0.2 ​%, and American Indians 0.1 ​%, indicating an underrepresentation of diverse racial groups, notably lower compared to real-world demographic data. In terms of ethnicity, only 17.6 ​% were Hispanic.
CONCLUSIONS: This study reveals significant demographic disparities in patients undergoing bariatric surgeries in clinical trials. This suggests a lack of generalizability, emphasizing the need for inclusive recruitment strategies to enhance health equity.
Claimed is the application of complementary peptides in oncology and cardiology. Potentially (i) a substance VPH (NH2 - Leu alpha N-Me-Phe Tyr Lys AlphaN-Me-Lys Val D-Tyr-COOH is anti-neoplastic; (ii) variation of the prim. structure of the peptide mimetic of calcium (Dillon, J. et al, Proc. Natl. Acad. Sci USA 88, 9726-9729) is an agent for hypertension or for tumours by inactivating the multi drug resistance gene prod.; (iii) peptide hSNI(B16-21) (3'-5', NH2 - Leu-Pro-Thr-His-Asp-Ala-COOH) is useful in diseases including tumours which occur together with insulin hyperproduction, and (iv) complementary proteins to insulin and insulin growth factors I and II are similar to the complementary peptides of oncoprotein E7 of the human papilloma virus type 16 and to the complementary peptides of the binding proteins binding to the retinoblastoma (RB) protein which regulates cell growth. Therefore, these proteins may be competitors for the RB-protein binding site, pref. binding RB protein 649-654. USE - The complementary peptides are administered to cancer patients as a potentially more potent anti-cancer agent which also shows fewer side effects than known agents. In the case of treatment of hypertension the suggested peptide mimetic of calcium could be an alternative to known calcium antagonists.
The invention discloses a preparation method of an anti-aging health food. The anti-aging health food is prepared from the following raw materials, by weight, 30-100 parts of poria cocos, 10-100 parts of balloonflower root, 10-50 parts of peach seed, 20-400 parts of polygonatum rhizome, 10-300 parts of ginseng, 20-300 parts of radix astragali, 10-50 parts of cyathula root, 20-200 parts of raw rehmannia root, 30-300 parts of prepared rehmannia root, 10-100 parts of tree peony bark, 10-100 parts of Chinese angelica, 15-100 parts of epimeddium, 10-80 parts of bitter orange, 15-100 parts of morinda officinalis and 20-100 parts of white peony root. The required food is prepared by steps of: washing the raw materials, immersing, decocting, concentrating, and preparing a preparation, etc. As the raw materials which are cheap in price are used to prepare the anti-aging health food, production cost is greatly reduced while composite anti-aging functions are satisfied. The prepared product has functions of invigorating qi and blood, promoting blood circulation to remove blood stasis, pacifying the five internal organs and regulating the balance of Yin-Yang, and has significant effects of raising immunity of the organism, enhancing physique, relieving physical fatigue and the like. In addition, the method is simple and the health food is convenient to prepare.
Participants will be treated with 16% topical MAL photosensitizer with a 1-hour incubation period. The light source used for skin illumination will be a visible light source (LED) with a wavelength of 643nm (Hygialux LLT1601®, KLD - ANVISA registration number 10245239012).
Social anxiety disorder is a prevalent and disabling condition for which effective long-term treatments need to be identified. Paroxetine is effective in treating the acute symptoms of social anxiety, but many patients achieve less than optimal response. CBT has also been effective in treating social anxiety disorder; thus,it may also be effective in augmenting paroxetine response. This study will examine the effects of paroxetine treatment alone and in combination with CBT among patients who achieve less than optimal response after an open trial with paroxetine.

Participants in this study will receive paroxetine for 12 weeks (Phase 1). After 12 weeks, participants who have completed this open trial but have achieved some but less than optimal response will move forward to Phase 2. To be eligible to move forward to Phase 2, patients must have achieved at least a 10% improvement in their open-trial Liebowitz Social Anxiety Scale Scores (LSAS) but still have an LSAS score of 30 or greater. Patients meeting these criteria will be randomly assigned to either add weekly sessions of CBT to their treatment or to continue taking paroxetine alone for another 16 weeks. Social anxiety symptoms, rates of response and remission, fear of negative evaluation, disability and quality of life will be assessed.
Cycle 1-4: Epirubicin i.v. 90 mg/m2, Cyclophosphamide i.v. 600 mg/m2 (One cycle = 14 days); Cycle 5-8:Paclitaxel i.v. 175mg/m2 (One cycle = 14 days) .
OBJECTIVE: OA is a chronic disease characterized by cartilage degeneration and inflammation, with no approved disease-modifying drugs. This study aimed to identify pathogenic genes and elucidate their mechanism in OA.
METHODS: We systematically identified pathogenic genes combined sing-cell and bulk transcriptome profiles of cartilage tissues in OA. Adenovirus carrying the serpin peptidase inhibitor clade E member 2 (serpinE2) or exogenous serpinE2 was injected into monosodium iodoacetate (MIA)-induced OA-model rats. Histological analysis, immunohistochemistry and Alcian blue staining were performed. In vitro, immunofluorescence, quantitative real-time PCR (RT-qPCR), ELISA and western blot assays were performed.
RESULTS: serpinE2 exhibited elevated expression and hypomethylation, showing a positive association with collagen pathway activities in patients with OA. Silencing serpinE2 aggravated MIA-induced knee cartilage degeneration in OA-model rats. Conversely, the intra-articular injection of exogenous serpinE2 ameliorated articular cartilage degeneration, reduced pain-related behavioural responses and relieve synovitis in MIA-induced OA-model rats. Exogenous serpinE2 not only attenuated the elevation of NLRP3, IL-1β and caspase1 expression levels but also restored the reduction in cell viability induced by lipopolysaccharide (LPS) in chondrocytes. Mechanistically, we found that exogenous serpinE2 inhibited LPS-induced reactive oxygen species (ROS) release and NF-κB signalling activation.
CONCLUSIONS: serpinE2 plays a protective role in cartilage and synovium tissues, suggesting that serpinE2 gene transfer or molecules that upregulate serpinE2 expression could be therapeutic candidates for OA.
The present phase II study evaluates the clinical outcomes and potential treatment-related toxicity following definitive ultra-high dose single fraction external beam radiation therapy (SDRT) in patients with localized adenocarcinoma of the prostate. A large body of data suggests that extreme hypofractionated radiation schedules, which employ ultra-high dose per fraction (≥7 Gy) in a small number of fractions (≤5), appear equal or superior to conventionally-fractionated (1.8-2.0 Gy/fraction) and moderately hypo-fractionated schemes (2.5-3.5 Gy/fraction) in terms of both tumor control and toxicity profiles. Modern computer-driven technology enables the implementation of ultra-high hypofractionated Image-Guided Radiotherapy (IGRT) safely. The Radiation Oncology team at Champalimaud Centre for the Unknown has been engaged in a large phase II study (HYPO) of extreme hypofractionation (9Gyx5) which accrued over 200 cases and, with a median follow-up of over 3 years, showed the safety and efficacy of this approach. The feasibility of SDRT in localized prostate cancer has been tested by the in a randomized phase II trial (PROSINT) comparing extreme hypofractionation as per the HYPO trial regimen vs. a single dose of 24Gy. While the long-term results of this study are still pending, its toxicity profile in both arms has been extremely good with no G3 adverse events at 2 years and superimposable biochemical response between the two regimens. Taken together, these observations provide the basis for the prospective clinical studies proposed herein.

Patients enrolled in the study will undergo image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT) with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility. A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility, while a urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking. Previously untreated patients with low and intermediate risk (NCCN criteria) localized prostate cancer will be treated with 24 Gy SDRT.

Patients will be followed at one and three months post-treatment, every 3 months for up to 12 months (+/- 4 weeks) and every 6 months thereafter. Acute and chronic toxicity evaluations will focus, though not exclusively, on urinary, rectal and sexual functions and will be assessed through validated EPIC questionnaires. Serum PSA values will be drawn on the same schedule as clinical follow-up. A multiparametric MRI will be performed at baseline, and at 6, 12 and 24 months following intervention. The study will be continuously monitored for a minimum of 5 years.
BACKGROUND: Hand hygiene is a crucial measure for the prevention of healthcare-associated infections (HAIs). The Hand Hygiene Excellence Award (HHEA) is an international programme acknowledging healthcare facilities for their leadership in implementing hand hygiene improvement programmes, including the World Health Organisation's Multimodal Improvement Strategy. This study aimed at summarising the results of the HHEA campaign between 2010 and 2021 and investigating the relationship between different hand hygiene parameters based on data from participating healthcare facilities.
METHODS: A retrospective analysis was performed on datasets from HHEA forms, including data on hand hygiene compliance, alcohol-based handrub (ABHR) consumption, and Hand Hygiene Self-Assessment Framework (HHSAF) scores. Descriptive statistics were reported for each variable. The correlation between variables was inspected through Kendall's test, while possible non-linear relationships between hand hygiene compliance, ABHR consumption and HHSAF scores were sought through the Locally Estimated Scatterplot Smoothing or logistic regression models. A tree-structured partitioning model was developed to further confirm the obtained findings.
RESULTS: Ninety-seven healthcare facilities from 28 countries in three world regions (Asia-Pacific, Europe, Latin America) were awarded the HHEA and thus included in the analysis. HHSAF scores indicated an advanced hand hygiene promotion level (median 445 points, IQR 395-480). System change (100 [95-100] points) and institutional safety climate (85 [70-95] points) showed the highest and lowest score, respectively. In most cases, hand hygiene compliance was above 70%, with heterogeneity between countries. ABHR consumption above 20 millilitres per patient-day (ml/PD) was widely reported, with overall increasing trends. HHSAF scores were positively correlated with hand hygiene compliance (τ = 0.211, p = 0.007). We observed a positive correlation between compliance rates and ABHR consumption (τ = 0.193, p < 0.001), although the average predicted consumption was stable around 55-60 ml/PD for compliance rates above 80-85%. Logistic regression and partitioning tree analyses revealed that higher HHSAF scores were more likely in the high-ABHR consumption group at cut-offs around 57-59 ml/PD.
CONCLUSION: Ten years after its inception, the HHEA proves to be a valuable hand hygiene improvement programme in healthcare facilities worldwide. Consistent results were provided by the different hand hygiene indicators and the HHSAF score represents a valuable proxy measure of hand hygiene compliance.
Epithelial ovarian cancer (EOC) remains a leading cause of gynecologic cancer mortality in women, with more than 22,000 deaths per year in the United States alone. Due to the lack of effective screening strategies and subtle early symptoms, eighty percent of newly diagnosed patients have disease that is advanced. Despite cytoreductive surgery and adjuvant paclitaxel-based and platinum-based chemotherapy, 5-year survival rates continue to be less than 40%. For patients who become resistant to the platinum compounds (defined as progressive disease while on a platinum-based chemotherapy regimen (refractory) or within 6 months of completing a platinum-based chemotherapy regimen (resistant)),the outlook is particularly poor, and often heralds multi-drug resistant disease.

At the present time, the management of ovarian cancer in the platinum refractory disease state is limited to palliative intent. Patients with advanced, bulky tumors, poor performance status and nutritional compromise are unlikely to respond to therapy and may be best served by supportive care. The clinical management of refractory disease requires both patience and persistence. A patient with platinum refractory disease is begun on one of the agents with activity and an evaluation of response is made every 6-8 weeks of therapy. As long as the patient shows no signs of disease progression, the therapy can be continued unless there is unacceptable toxicity. When progressive disease is observed, another of the list of available agents can be used. It is likely that patients will receive multiple single agents during the chronic phase of their illness. Every effort should be made to balance disease response with toxicity and quality of life.

Based on this rational, this trial will be conducted to evaluate the safety and efficacy of panitumumab, a human antibody targeted to the EGF-R, and Gemcitabine, in treating women with recurrent platinum-refractory/resistant EOC. Our aim is to determine the safety and feasibility of gemcitabine and panitumumab therapy in this population and once completed, to proceed with an efficacy study using an expanded cohort.
BACKGROUND: Ventricular tachycardia (VT) diagnosis is challenging due to the similarity between VT and some forms of supraventricular tachycardia, complexity of clinical manifestations, heterogeneity of underlying diseases, and potential for life-threatening hemodynamic instability. Clinical decision support systems (CDSSs) have emerged as promising tools to augment the diagnostic capabilities of cardiologists. However, a requirements analysis is acknowledged to be vital for the success of a CDSS, especially for complex clinical tasks such as VT diagnosis.
OBJECTIVE: The aims of this study were to analyze the requirements for a VT diagnosis CDSS within the frameworks of knowledge and practice and to determine the clinical decision support (CDS) needs.
METHODS: Our multidisciplinary team first conducted semistructured interviews with seven cardiologists related to the clinical challenges of VT and expected decision support. A questionnaire was designed by the multidisciplinary team based on the results of interviews. The questionnaire was divided into four sections: demographic information, knowledge assessment, practice assessment, and CDS needs. The practice section consisted of two simulated cases for a total score of 10 marks. Online questionnaires were disseminated to registered cardiologists across China from December 2022 to February 2023. The scores for the practice section were summarized as continuous variables, using the mean, median, and range. The knowledge and CDS needs sections were assessed using a 4-point Likert scale without a neutral option. Kruskal-Wallis tests were performed to investigate the relationship between scores and practice years or specialty.
RESULTS: Of the 687 cardiologists who completed the questionnaire, 567 responses were eligible for further analysis. The results of the knowledge assessment showed that 383 cardiologists (68%) lacked knowledge in diagnostic evaluation. The overall average score of the practice assessment was 6.11 (SD 0.55); the etiological diagnosis section had the highest overall scores (mean 6.74, SD 1.75), whereas the diagnostic evaluation section had the lowest scores (mean 5.78, SD 1.19). A majority of cardiologists (344/567, 60.7%) reported the need for a CDSS. There was a significant difference in practice competency scores between general cardiologists and arrhythmia specialists (P=.02).
CONCLUSIONS: There was a notable deficiency in the knowledge and practice of VT among Chinese cardiologists. Specific knowledge and practice support requirements were identified, which provide a foundation for further development and optimization of a CDSS. Moreover, it is important to consider clinicians' specialization levels and years of practice for effective and personalized support.
The present invention provides a physiologically compatible conductive agent comprising (a) a long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %; (b) an unbranched or branched alcohol having from 1 to about 4 carbon atoms present in an amount up to about 70 wt. %; and (c) the balance water. The present invention also provides a physiologically compatible conductive agent comprising long chain water-soluble ionic polymeric thickening agent selected from the group consisting of a copolymer of methyl vinyl ether and maleic anhydride, carboxy polymethylene polymer, and mixtures thereof, present in an amount from about 0.05 wt. % to about 10 wt. %; (b) a surface tension reducing amount of a surfactant; and (c) the balance water. The present invention further provides methods for transmitting electrical or ultrasonic impulses to a surface in contact with a transducer with a conductivity gap by applying to the conductivity gap the novel physiologically compatible conductive agents. The present invention also provides methods for preparing the physiologically compatible conductive agents of the present invention.